COVID-19 has affected almost all countries in the world. Every other country is constantly working towards its treatment and development of vaccines, with little to no success so far. Recently, several regimens have been tried as antiviral medicine. Among these medicines, Favipiravir is considered a broad-spectrum antiviral with the spectrum of activity noted against a wide range of RNA viruses & a good oral antiviral drug with > 97% bioavailability. It has already proved its safety profile as it has received FDA indication for drug-resistant Influenza. There has been increasing evidence of favorable outcome against COVID-19 in terms of early viral clearance & quicker symptomatic relief however, most of these studies lack strong statistical significance & are not peer-reviewed. Subjects will be categorized into two arms based on the severity of infection due to COVID-19 defined by NMC guidelines. Each arm will have respective two groups as the study drug group and control group. Based on the sample size calculation, subjects will be stratified & randomly enrolled in the study after checking the eligibility criteria at the screening visit. About 276 mild patients will be recruited for this trial and 400 moderate patients (including 10% loss ). Study arm groups will receive a Favipiravir treatment of 1800 mg PO BID on day 1, then 800 mg PO BID from day 2 onwards and control groups will receive the same quantity of Placebo. Treatment will be continued till 5 days after for mild groups and 10 days for moderate groups. Eligible patients will be randomly assigned (1:1) to either Favipiravir or Placebo among mild cases; and Favipiravir or Remdesivir among moderate cases. Randomization will be stratified by age group (18 to 40 years, 40 to 60 years and 60 to 80 years) and co-morbidity. The permuted block (30 patients per block) randomization sequence, including stratification, will be prepared by a statistician using STATA-15 software. Eligible patients will be allocated to the respective arm and will receive individually numbered packs, according to the sequence order as informed by the hotline. Informed written consent will be taken from the participants before commencing the study. All safety data, patient's baseline, clinical outcome data, data from endpoints and variables should be reported by the clinician and his/her team in a pre-instructed case report form (CRF) via a designated website. It is our assumption that if the study results come favorable, Favipiravir, when used in mild or moderate cases, might prevent progression of the disease to higher severity, helps achieve viral clearance early so as to positively impact disease transmission in the community, increase the quality of life by quicker symptom recovery & decrease health burden by shortening the length of stay at the hospital. These findings can also be useful in international scenarios where the world is looking for innovative measures to curb COVID-19 infection. The study findings will be disseminated within and outside the country and will be published in peer-reviewed journals.
COVID-19 stands for 2019 novel coronavirus or 2019-nCoV which is a new virus linked to the
same family of viruses as Severe Acute Respiratory Syndrome (SARS), & hence named as
SARS-CoV-2. It has been revealed that SARS-CoV-2 has a genome sequence that is 75%-80%
identical to that of SARS-CoV. Since its first discovery in Wuhan, China in late December, it
has now become a pandemic disease claiming more than nine hundred forty-five thousand deaths
world-wide so far. Majority of the patients are asymptomatic or mild symptomatic, & recovery
without any treatment. While there is disproportionately higher mortality among elderly &
people with co-morbidities like hypertension, diabetes, obesity, heart disease or any
immunocompromised status. Recently, several regimens have been tried as antiviral medicine.
Among these medicines, Favipiravir is considered a broad-spectrum antiviral with spectrum of
activity noted against a wide range of RNA viruses namely Influenza, West Nile virus, Yellow
fever virus, Food & mouth virus, Flavivirus, Arenavirus, Bunyavirus & Alpha virus. In the
USA, Japan & China, it has been approved for use in resistant Influenza. Regarding use of
Favipiravir in COVID19, there have been some studies with limited data. The earlier Chinese
study that compared between Favipiravir (35 patients) versus Lopinavir/Ritonavir (45
patients) among mild to moderate cases showed a trend towards earlier improvement in CT scan
& quicker viral clearance in Favipiravir arm with lesser side effects comparatively. Another
randomized clinical trial in China conducted on patients with COVID19 pneumonia (moderate)
failed to demonstrate a significant difference in clinical recovery rate at day 7 between
Favipiravir (116 patients) versus Umifenovir (112 patients) however, Favipiravir was
associated with earlier relief of pyrexia & cough in comparison Another multicenter, open
label, randomized phase II/III trial conducted in Russia on moderate COVID19 infection
comparing Favipiravir against standard of care in total 60 patients randomized into three
treatment groups with 20 patients each: Favipiravir 1600/600 mg, Favipiravir 1800/800 mg, or
Standard of care (which included, hydroxychloroquine or chloroquine versus
lopinavir/ritonavir versus no etiotropic treatment) concluded that Favipiravir enabled viral
clearance in 62.5% patients within 4 days with good safety data, no matter which dosing was
used. There has been an observational study on 2141 patients in Japan that showed good
recovery among mild (not requiring oxygen), moderate case (requiring oxygen) or younger
patients (59 years or younger) whereas poor prognosis in severe (requiring mechanical
ventilation or ECMO) or older patients (60 years or older). The most common adverse events
were hyperuricemia (335 patients; 15.52%) followed by liver injury or liver function test
abnormalities (159 patients; 7.37%) in this study. Similarly, the open label randomized ,
multicenter clinical trial was conducted in 150 patients to evaluate the efficacy and safety
of Favipiravir plus standard supportive care ( Favipiravir treatment arm, versus standard
supportive care alone ( control arm ) across seven clinical sites in India.
It was evaluated among mild to moderate patients, randomized within a 48 hours window of
testing RT-PCR positive for COVID-19 . The patients received Favipiravir tables of 3,600 mg
(1,800 mg BID) (Day 1) + 1,600 mg (800 mg BID) (Day 2 or later) for up to maximum of 14 days
, along with standard supportive care . The results from this Phase 3 trial conducted by
Glenmark showed numerical improvement for the primary efficacy endpoint with 28.6% faster
viral clearance in the overall population (Hazard Ratio 1.367 [95%CI 0.944,1.979]; p=0.129).
Additionally , 69.8 % of patients in the Favipiravir treatment arm achieved clinical cure by
Day 4, which was statistically significant compared to 44.9% observed in the control group
(p=0.019). Likewise, Glenmark's Favipiravir was well tolerated with no serious adverse events
or death in the Favipiravir treated arm but adverse events were reported in 26 patients in
Favipiravir treatment arm. However, adverse events were mild to moderate and none led to drug
discontinuation and dosing adjustments. This trial demonstrated statistically significant
faster time to clinical improvement with Favipiravir treatment in Mild to moderate COVID-19
patients compared to the control group. Additionally, An open-label, nonrandomized,
before-after controlled study was conducted in an isolation ward of the national clinical
research center for infectious diseases at Shenzhen, China.35 patients was enrolled in the
FPV arm and the 45 patients in the control arm, all baseline characteristics were comparable
between the two arms. From 30 January to 14 February 2020, laboratory-confirmed patients with
COVID-19 were consecutively screened, and eligible patients were included in the FPV arm of
the study. Patients who had initially been treated with antiviral therapy with LPV/RTV from
24 January to 30 January 2020 were screened, and eligible patients were included in the
control arm of the study. The dose was 1600 mg twice daily on Day 1 and 600 mg twice daily on
Days 2-14. LPV/RTV (AbbVie Inc., 200 mg/50 mg per tablet) were given orally. The dose was LPV
400 mg/RTV 100 mg twice daily. Both FPV and LPV/RTV were continued until the viral clearance
was confirmed or until 14 d had passed. For the 35 patients enrolled in the FPV arm and the
45 patients in the control arm, all baseline characteristics were comparable between the two
arms. A shorter viral clearance time was found for the FPV arm versus the control arm (median
(interquartile range, IQR), 4 (2.5-9) d versus 11 (8-13) d, P < 0.001). The FPV arm also
showed significant improvement in chest imaging compared with the control arm, with an
improvement rate of 91.43% versus 62.22% (P = 0.004). After adjustment for potential
confounders, the FPV arm also showed a significantly higher improvement rate in chest
imaging. Multivariable Cox regression showed that FPV was independently associated with
faster viral clearance. In addition, fewer adverse events were found in the FPV arm than in
the control arm.In this open-label before-after controlled study, FPV showed better
therapeutic responses on COVID-19 in terms of disease progression and viral clearance.These
preliminary clinical results provide useful information of treatments for SARS-CoV-2
infection. Doses of Favipiravir ranged widely across studies, from 400 mg up to 6000 mg
loading doses, with the more common regimens being 1200 mg per day, split into twice or three
times daily doses. 494 Studies were screened, 55 studies assessed for full text eligibility,
29 studies were included. Hyperuricemia was shown as the side effects.
Drug: Favipiravir
Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19
Other Name: Favir 200
Drug: Placebo
Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19
Drug: Remdesivir
Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to Remdesivir Injection in the patients with moderate COVID-19
A. Inclusion Criteria:
1. Minimum 18 - 80 years of age
2. Clinical Diagnosis of COVID 19 with RT-PCR test for SARS-CoV-2 (If a patient is
COVID19 positive based on Antigen test, they can participate in the trial while
awaiting result form PCR test with Ct-value)
3. Signed informed consent provided by patient's or patient's healthcare proxy.
4. Fulfills enrollment criteria ( within 6 days of symptoms onset)
5. Willing to practice celibacy OR take contraception during the study & within 7 days
after treatment
6. Mild clinical condition with at least 3 of these of these symptoms : fever, cough,
malaise/headache
7. Moderate clinical condition with at least 3 of these of these symptoms : fever, cough,
malaise/headache
B. Exclusion Criteria:
1. Pregnant (female of childbearing age with positive urine pregnancy test) or
miscarriage or within 2 weeks after delivery
2. Severe or critical clinical condition as per NMC clinical guideline for COVID19
Chronic liver with ALT/AST increased 5 times higher than the upper limit of normal or
with Child Pugh C
3. Creatinine clearance (Cockcroft-Gault Equation) < 30 ml/min or having
hemodialysis/peritoneal dialysis
4. Known allergy or hypersensitivity to Favipiravir
5. Gout or history of gout or hyperuricemia two times the upper limit of normal
6. If using Remdesivir, Lopinavir-ritonavir, Hydroxychloroquine or any other antiviral
drug with potential effect against SARS-CoV-2 virus
7. Lactating female
8. Asymptomatic COVID-19 cases
9. Mild COVID-19 cases not meeting the inclusion criteria symptoms
10. Moderate COVID-19 cases not meeting the inclusion criteria symptoms
(*All female patients age 18 - 50 years will be screened for pregnancy by urine test & any
pregnant patient will be excluded. Also, the patient must be consented to take
contraception or practice celibacy during the study period & until 7 days after treatment.
Since the expected wash out period of the study drug Favipiravir is 10hrs minimum to
27.5hrs maximum (half life is 2-5.5hrs), it is a safe practice to avoid conception for 1
week after stopping the drug of interest)
Armed Police Force Hospital
Kathmandu, Bagmati, Nepal
Charak Memorial Hospital
Pokhara, Gandaki, Nepal
Prabhat Adhikari, MD
+977-9843003527
prabhatadhikari@gmail.com
Janak Koirala, MD
+977 9818762117
jkoirala2002@gmail.com